TABLE 1.
Infection of trCrFK cells by FIV
| Cella | Abb | Infectionc by the following virus:
|
||||||
|---|---|---|---|---|---|---|---|---|
| Mock | VICSF | Ch | Petaluma | ChSU | ChTM | ChV35 | ||
| Parent | None | − | + | + | +++ | + | ++ | + |
| X4 | − | − | − | − | − | − | − | |
| R3 | − | + | + | +++ | + | ++ | + | |
| R5 | − | + | + | +++ | + | ++ | + | |
| CXCR4 | None | − | + | + | ++++ | + | ++ | + |
| X4 | − | − | − | + | − | − | − | |
| R3 | − | + | + | ++++ | + | ++ | + | |
| R5 | − | + | + | ++++ | + | ++ | + | |
| CCR3 | None | − | +++ | +++ | ++++ | +++ | ++ | +++ |
| X4 | − | − | − | − | − | − | − | |
| R3 | − | ++ (53) | ++ (49) | ++++ | ++ (47) | ++ | ++ (44) | |
| R5 | − | +++ | +++ | ++++ | +++ | ++ | +++ | |
| CCR5 | None | − | +++ | +++ | ++++ | +++ | ++ | +++ |
| X4 | − | − | − | − | − | − | − | |
| R3 | − | +++ | +++ | ++++ | +++ | ++ | +++ | |
| R5 | − | ++ (62) | ++ (61) | ++++ | ++ (59) | ++ | ++ (54) | |
trCrFK cells used in this study included nontransfected cells (parent) or cells transfected with the human CCR3, CCR5, or CXCR4 chemokine receptor. All trCrFK cell lines expressed endogenous feline CXCR4.
Ab, antibody trCrFK cells were infected in the absence of anti-chemokine receptor antibodies (none) or in the presence of antibodies to human CCR3 (R3), CXCR4 (X4), or CCR5 (R5).
trCrFK cells were infected with either 104.5 TCID50 of V1CSF, FIV-Ch (Ch), or Petaluma/ml or 102.5 TCID50 of FIV-ChSU (ChSU), FIV-ChTM (ChTM), or FIV-ChV35 (ChV35)/ml. Infection was assessed after 72 h by PCR amplification of the FIV pol gene from genomic DNA (−, not detectable; +, nested PCR required; ++++, +++, and ++, detectable by single-round PCR with decreasing abundance. Graded responses are measured relative to cells infected in the absence of antibodies, with percent decreases in viral DNA given in parentheses.